StopDown
PharmEasy logo
Company

PharmEasy

Online pharmacy and health platformpharmeasy.in ↗LinkedIn ↗X ↗Instagram ↗
Healthcare & Life SciencesMumbaiFounded 2019

PharmEasy revenue, valuation and funding

PharmEasy reported revenue of ₹6,618.5 crore in FY26 (the year to March 2026), against ₹5,664.2 crore in FY24, with a net loss of ₹520 crore, per filings and statements as reported.

PharmEasy revenue, valuation and funding
Revenue (FY26)₹6,618.5 crore
Revenue (FY24)₹5,664.2 crore
Net loss (FY26)₹520 crore
Net loss (FY24)₹2,531 crore

Figures from filings and statements as reported; the table below carries each year with its source.

PharmEasy key facts

  • What it doesOnline pharmacy and health platform Story
  • Founded2015 Profile
  • HeadquartersMumbai
  • Last round₹1,700 crore (about $193 million), Debentures (debt), Sep 2025 Profile
  • StatusPrivate
₹6,618.5 croreFY26 revenue (API Holdings)FY26 Profile
₹520 croreFY26 loss (API Holdings)FY26 Profile

PharmEasy revenue and profit by year

PharmEasy revenue and profit by financial year, ₹ crore, from filings and statements as reported
YearRevenueProfit or lossExpensesNoteSource
FY26₹6,618.5 crore₹520 crore loss₹7,146.7 croreAPI Holdings (parent of PharmEasy), consolidated; revenue from operations, up 12.7%; total income ₹6,689.2 crore; FY25 left out because sources differ on its revenue and loss Inc42, FY26 results
FY24₹5,664.2 crore₹2,531 crore lossAPI Holdings (parent of PharmEasy), consolidated; operating revenue, as shown with the FY25 results Outlook Business, FY25 and debentures

As reported for each financial year; where sources disagree the figure is left out rather than picked.

Funding rounds

PharmEasy funding rounds, as announced
WhenRoundAmountInvestorsSource
2022Debentures (debt)$300 million (₹2,220 crore)Goldman Sachs Inc42, PharmEasy's Uneasy State
2023Rights issue (equity)₹1,300 crore from Ranjan PaiRanjan Pai, chairman of Manipal Group Inc42, PharmEasy's Uneasy State
2024Fundraise (equity)₹800 crore from Ranjan Pai's family officeRanjan Pai's family office Inc42, PharmEasy's Uneasy State
Sep 2025Debentures (debt)₹1,700 crore (about $193 million)Lenders not named in the report Outlook Business, FY25 and debentures

Timeline

The short version

Deals and partnerships

PharmEasy deals and partnerships, as announced
WhenWithWhatPriceSource
Jun 2021Thyrocare TechnologiesListed diagnostics company bought by API HoldingsAbout $600 million Inc42, PharmEasy's Uneasy State
Aug 2026Thyrocare Technologies (stake sale)Docon Technologies sold about 9.90% of Thyrocare, keeping 51.02%; buyer not namedNot disclosed Entrepreneur India, debt repaidMoneycontrol, debt-free parent

Products

People

Questions people ask about PharmEasy

What is PharmEasy's revenue?

API Holdings, the parent of PharmEasy, reported revenue from operations of ₹6,618.5 crore for FY26 (the year to March 2026), up 12.7% on the year before, with total income of ₹6,689.2 crore. These are consolidated figures for the whole group, including diagnostics arm Thyrocare, not for the PharmEasy app alone. Inc42, FY26 results

Is PharmEasy profitable?

No. API Holdings, the parent of PharmEasy, posted a consolidated net loss of ₹520 crore for FY26, 67% lower than the year before, on revenue from operations of ₹6,618.5 crore. Its chief executive has set September 2027 as the target for profit outside Thyrocare, per Moneycontrol on 5 October 2026. Inc42, FY26 resultsMoneycontrol, debt-free parent

What is PharmEasy's valuation?

Inc42 reports that PharmEasy's valuation fell about 90% to $456 million during its 2023 rights issue and the fundraises that followed in 2024. Ranjan Pai put ₹1,300 crore into the rights issue and ₹800 crore through his family office in 2024. No newer valuation event appears in the sources for this page. Inc42, PharmEasy's Uneasy State

Who owns PharmEasy?

PharmEasy is owned by API Holdings, a private group backed by TPG, Prosus Ventures, Temasek, CDPQ and Eight Roads, per Moneycontrol. Manipal Group chairman Ranjan Pai invested ₹1,300 crore in the 2023 rights issue and ₹800 crore through his family office in 2024, per Inc42. Through its unit Docon Technologies, API Holdings holds 51.02% of listed Thyrocare. Moneycontrol, debt-free parentInc42, PharmEasy's Uneasy StateEntrepreneur India, debt repaid

Is PharmEasy going for an IPO?

No new IPO filing is reported in the sources for this page. API Holdings, PharmEasy's parent, says it could still list, or merge with Thyrocare, later, after first reaching profit outside Thyrocare, a goal it sets for September 2027, per Moneycontrol on 5 October 2026. An earlier plan to raise ₹6,250 crore through an IPO in 2021 was withdrawn because of market volatility, per Inc42. Moneycontrol, debt-free parentInc42, PharmEasy's Uneasy State

Every line links to the article it came from, written in our own words. Not investment advice. Profile updated 2026-11-11.

Stories cover its results, news, stake sale and people. Sectors: Healthcare & Life Sciences. Based in Mumbai and Navi Mumbai. Stories run from 6 March 2026 to 12 October 2026.

The founders

Siddharth Shah

Co-founder
in

Dharmil Sheth

Co-founder
in

Dhaval Shah

Co-founder

Who put in money

Head to head: PharmEasy vs Tata 1mg →

Every story on PharmEasy

For PharmEasy: add the “Featured on StopDown” badge

Put this on your website's press or media page. It links readers to PharmEasy on StopDown.

Featured on StopDownFeatured on StopDown, dark

· About the badge